CASC11 and prostate cancer: This overexpression of CASC11 leads to the inhibition of miR-145 and the overexpression of IGF1R, resulting in the activation of the PI3K/AKT/mTOR signaling pathway, which influences the malignant phenotype of prostate cancer cells (Capik et al., 2021).